Jim Cramer: Joby Is 'Losing Too Much Money'

Group 1: Aquestive Therapeutics - Jim Cramer described Aquestive Therapeutics, Inc. as a "very interesting spec" [1] - Piper Sandler analyst David Amsellem maintained an Overweight rating on Aquestive Therapeutics and raised the price target from $5 to $8 [1] - Shares of Aquestive Therapeutics gained 2% to close at $5.69 [4] Group 2: Amphenol Corporation - Cramer praised Amphenol Corporation as a "great" stock and recommended staying in the cable play [1] - Amphenol reported fiscal third-quarter 2025 results with quarterly sales increasing by 53% year-on-year to $6.19 billion, exceeding the analyst consensus estimate of $5.53 billion [1] - Adjusted EPS for Amphenol was 93 cents, beating the analyst consensus estimate of 80 cents [1] - Amphenol shares fell 0.3% to settle at $143.47 [4] Group 3: Joby Aviation - Cramer criticized Joby Aviation, Inc. for "losing too much money" [2] - Joby Aviation's third-quarter earnings report showed losses of 48 cents per share, missing the Street estimate for losses of 19 cents [2] - Joby Aviation shares rose 3.7% to settle at $16.35 [4]